We have examined the phosphorylation and the serine/threonine-specific kinase activity of the 
coded by v-fms, v-src, v-sis, polyoma virus middle-sized tumor antigen, and Ha-ras increased the apparent molecular weight and phosphorylation of the Raf-1 protein, while expression of the nuclear oncogene and protooncogene products encoded by v-fos and c-myc did not. Changes in electrophoretic mobility and phosphorylation occurred rapidly in response to treatment of cells with platelet-derived growth factor, acidic fibroblast growth factor, epidermal growth factor, and the protein kinase C activator phorbol 12-myristate 13-acetate, but not insulin. The phosphorylation of the Raf-1 protein occurred primarily on serine and threonine residues. However, a subpopulation of Raf-1 molecules was phosphorylated on tyrosine residues in cells transformed by v-src or stimulated with platelet-derived growth factor. Transformation by v-src, or treatment with platelet-derived growth factor or phorbol 12-myristate 13- acetate, activated the Raf-1-associated serine/kinase activity as measured in immune-complex kinase assays. These findings suggest that proliferative signals generated at the membrane result in the phosphorylation of the Raf-1 protein and the activation of its serine/threonine kinase activity. Raf-1 activation may thus serve to transduce signals from the membrane to the cytoplasm and perhaps on to the nucleus.
Cytoplasmic serine/threonine protein kinases are candidate signal transducers linking growth stimulatory events at the cell membrane to changes which occur in the cytoplasm and nucleus. Two serine/threonine kinases normally residing in the cytoplasm have been shown to be activated by mitogenic or oncogenic signals, protein kinase C (1), and a ribosomal S6 kinase (2) . We have examined the role of a third serine/ threonine kinase, the product of the Raf-J protooncogene (formerly c-raf) (3, 4) , in mitogenesis and oncogenesis. Raf-) is the cellular homologue of v-raf, the transforming gene of the murine sarcoma virus 3611 (5) . Transfection of human and rodent tumor DNAs, as well as cytogenetic studies have implicated Raf-l in a variety of common human and rodent neoplasms (6) . The product of the Raf-J gene is a 74-kDa cytoplasmic protein which has an associated serine/threonine-specific protein kinase activity (3, 4, 7, 8) . The Raf-1 protein can be divided into three domains: a cysteine-rich domain, a serine/threonine-rich domain, and a carboxylterminal kinase domain (4, 6, 9) . Oncogenic activation of the Raf-1 protein can occur by an amino-terminal truncation which removes a putative regulatory region (6) . In addition, when amino-terminal truncated Raf-1 protein is injected into serum-starved NIH 3T3 cells, DNA synthesis is efficiently induced in those cells (10) .
In the following study we examine the phosphorylation and protein kinase activity of the Raf-1 protein in response to oncogenic transformation or mitogen treatment of mouse 3T3 cells. Our results suggest that the Raf-1 protein can be activated by tyrosine and/or serine and threonine phosphorylation as a result of direct or indirect action of membranebound oncogene products and growth factor receptors.
MATERIALS AND METHODS
Mitogens. Platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) (receptor grade) were from Collaborative Research (Waltham, MA). Acidic fibroblast growth factor (FGF) (0.4 ng of protein per unit from P. A. D'Amore, Childrens Hospital, Boston) and PDGF were used at a concentration of 10 half-maximal units/ml except where noted (1 unit induces half-maximal stimulation of [3H]thymidine uptake by 3T3 cells). Bovine pancreatic insulin, phorbol 12-myristate 13-acetate (PMA), and dibutyryl cAMP were from Sigma.
Radiolabeling of Cells and Immunoprecipitation. For 32p labeling, cells were incubated at 370C for 3 hr in phosphatefree medium supplemented with [32P]orthophosphate at 2 mCi/ml (1 Ci = 37 GBq) and 2% (vol/vol) platelet-poor plasma. For growth-factor experiments, mitogens were added directly to the labeling medium. Assays were terminated by the addition of ice-cold isotonic phosphate-buffered saline containing 100 ,uM sodium orthovanadate. Cell lysates were prepared as described (11) , the lysates were normalized for protein content, and labeled proteins were immunoprecipitated for 3 hr at 4°C with anti-phosphotyrosine [Tyr(P)] antiserum (12) or with anti-Raf-1 antiserum (anti-SP63) (13) . Immune complexes were precipitated and washed as described (11) prior to sodium dodecyl sulfate (SDS)/PAGE analysis.
Phosphatase Analysis. Phosphatase assays were performed as in the figure legend and as described (14) .
Peptide Mapping and Phospho Amino Acid Analysis. 32p-labeled proteins were resolved by SDS/PAGE, extracted from the gels, and subjected to trypsin digestion as described (15) . Labeled peptides were separated on thin-layer cellulose plates by electrophoresis at pH 1.9 for 20 min at 1000 V followed by ascending chromatography as described (16) . Phospho amino acid analysis of phosphorylated proteins was performed as described (15) .
Protein Kinase Assays in Vitro. Immune complexes were prepared as described above. Immunoprecipitated Abbreviations: PDGF, platelet-derived growth factor; EGF, epidermal growth factor; FGF, fibroblast growth factor; PMA, phorbol 12-myristate 13-acetate; T, tumor; Tyr(P), phosphotyrosine; SDS, sodium dodecyl sulfate. §To whom reprint requests should be addressed.
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protein was then assayed for the ability to phosphorylate histone type V-S in vitro as described (8) .
RESULTS
PDGF and Membrane-Bound Oncogene Products, but Not Nuclear Oncogene Products, Alter the Electrophoretic Mobility of the Raf-1 Protein. The Raf-1 protein was examined in 3T3 cells transformed by the v-fms and v-src oncogene products by using immunoblot analysis. As seen in Fig. 1A , there is a population of Raf-1 molecules in both v-fms-and v-src-transformed cells which migrates more slowly than the Raf-1 molecules in quiescent 3T3 cells. No change in the mobility of Raf-1 was observed in Rat-1 cells transformed by v-fos or 3T3 cells transformed by overexpression of the c-myc gene (Fig. 1B) .
We next determined whether changes in Raf-1 protein mobility could be observed after addition of the growth factor PDGF to cells (Fig. 1A) (Fig. 2) . Alterations in Raf-1 protein phosphorylation were first examined in quiescent BALB/3T3 cells treated for 5 min with the following 3T3 cell mitogens: EGF, FGF, PDGF, and PMA (22, 23) . In immunoprecipitates from mitogen-treated cells, the Raf-1 protein exhibited a decreased mobility and increased phosphate content as compared to untreated quiescent cells ( Fig. 2A) .
Treatment for 24 hr with the Tyr(P) phosphatase inhibitor sodium orthovanadate also increased the phosphorylation and molecular mass of the Raf-1 protein ( Fig. 2A) . However, when quiescent 3T3 cells were treated with insulin for 5 min, or with dibutyryl cAMP, an activator of the cAMP-dependent protein kinase, no size change or increased phosphorylation of the Raf-1 protein was observed ( Fig. 2A) .
Expression Experiments were initiated on density-arrested monolayers as described (11) . Growth factors were added directly to the medium and incubation continued at 37°C. Transformed cell lines were not fed with fresh medium for at least 48 hr prior to use. Cell lysates were prepared and equalized for protein content before electrophoretic separation on 7.5% SDS/PAGE and transfer to nitrocellulose filters as described (17) . Protein blots were probed with anti-Raf-1 antibody (13) and immunological reactions were identified by using an alkaline phosphatase detection system. (A) Raf-1 proteins in 3T3 cells were transformed by the v-src (src) (18) or v-fms (fms) (17) (20) . 45b is an NIH 3T3 cell line expressing polyoma virus middle-sized T antigen under the control of the dexamethasone-inducible murine mammary tumor virus promoter (21) . 45b+, 45b cells treated for 16 hr with 5 "M dexamethasone to induce middle-sized T antigen synthesis; 45b-, untreated 45b cells. (C) Quiescent BALB/3T3 cells were chronically treated with PMA at 250 ng/ml for 48 hr to remove PMA binding sites and protein kinase C activity. PMA, chronically treated quiescent cells treated for an additional 5 min with PMA at 50 ng/ml. PDGF, chronically treated quiescent cells treated for 5 min with PDGF (10 units/ml). Also shown are quiescent BALB/3T3 cells (not pretreated with PMA) (C), treated for 5 min with PDGF (10 units/ml), PMA (50 ng/ml), or biologically inactive PMA (phorbol 13-butyrate) (50 ng/ml). virus middle-sized tumor (T) antigen oncogenes. We also examined Raf-1 protein phosphorylation in cells where expression of the polyoma' virus middle-sized T oncogene is under the control of the dexamethasone-regulatable murine mammary tumor virus promoter. Addition ofdexamethasone (5 ,uM for 16 hr) to this cell line, 45b, results in the appearance of anchorage-independent growth concomitant with the induction of middle-sized T antigen synthesis (21) . Treatment of quiescent 45b cells with dexamethasone resulted in an increase in phosphorylation and apparent molecular mass of the Raf-1 protein when compared to the Raf-1 protein from untreated 45b cells (Fig. 2B) . The cells appeared more refractile and the saturation density of the cultures increased after the addition of dexamethasone (data not shown). Dexamethasone treatment of control quiescent BALB/3T3 cells did not result in any alterations ofthe Raf-1 protein or cellular morphology (data not shown). These results suggest that the changes in Raf-1 protein phosphorylation and mobility observed in transformed cells are due to oncogene expression and correlate with the acquisition of the transformed state.
We next examined the effect of PMA on the migration and phosphorylation of the Raf-1 protein to determine if the changes observed in response to oncogenic transformation or growth-factor stimulation could be correlated with the activation of protein kinase C (Fig. 2C) (Fig. 2C) . Subsequent treatment of chronically treated cells with PMA (50 ng/ml for 5 min) still showed no change in the Raf-1 protein (Fig. 2C) . However, treating these cells for 5 min with PDGF did increase the phosphate content and molecular mass of the Raf-1 molecules (Fig. 2C) . These results suggest that while PMA activation of protein kinase C can affect the mobility and phosphorylation state of the Raf-1 protein, there are mechanisms independent of protein kinase C through which growth factors can bring about this change.
Electrophoretic Mobility Changes in Raf-1 Protein Are Due to Phosphorylation. To confirm that the changes in Raf-1 protein mobility were due to phosphorylation, the Raf-1 protein immunoprecipitates from PDGF-stimulated and quiescent 3T3 cells were treated with potato acid phosphatase. Fig. 3 shows that phosphatase treatment decreased the apparent molecular mass of Raf-1 molecules in PDGFstimulated cells from a molecular mass of =76 kDa to =72 kDa and in unstimulated cells from 74 kDa to a molecular mass identical to that of the phosphatase-treated Raf Since many of the growth factor receptors and membrane oncogene products have associated tyrosine kinase activities, the Raf-1 protein was examined to determine ifany ofthe increased phosphorylation of the protein could be due to phosphorylation on tyrosine residues. First, Tyr(P)-containing proteins were immunoprecipitated by using an antibody which specifically recognizes Tyr(P) residues from quiescent 3T3 cells and v-src-transformed cells or from quiescent and PDGF-treated 3T3 cells overproducing the Raf-1 protein (10-fold overproduction). Protein blots of the anti-Tyr(P) immunoprecipitates were then probed with antiRaf-1 antibody. Fig. 4A shows that the Raf-1 protein is immunoprecipitated by the anti-Tyr(P) antisera from vsrc-transformed cells and from PDGF-treated Raf-1 overproducer cells (c-raf*) but not from quiescent cells. To continue this examination, quiescent cells stimulated with PDGF and v-src-transformed cells were incubated with [32P]orthophosphate and labeled proteins were immunoprecipitated with either the anti-Raf-1 antibody or the anti-Tyr(P) antibody. Only in PDGF-stimulated and v-src-transformed cells did the anti-Tyr(P) antibody precipitate a protein whose migration corresponded with at least some of the Raf-1 molecules found in these cells. Two-dimensional tryptic phosphopeptide mapping revealed that the proteins immunoprecipitated by the anti-Tyr(P) and anti-Raf-1 antisera from the PDGF-treated cells and by the anti-Raf-1 antibody from unstimulated control cells shared a similar set of 32P-labeled peptides (Fig.  4C) . The identity of this set of peptides was confirmed by mixing 32P-labeled peptides immunoprecipitated by the antiTyr(P) and anti-Raf-1 antisera from the PDGF-treated cells (data not shown). Identical results were observed in immunoprecipitates from v-src-transformed cells (data not shown). The tryptic maps also revealed that there are a number of peptides characteristic of the Raf-1 protein observed from control cells as well as from the PDGF-stimulated and v-src-expressing cells (Fig. 4C) ; however, the Raf-1 molecules from the PDGF-stimulated cells contain additional 32P-containing peptides that are not observed in control or v-src-transformed cells (Fig. 4C) .
Phospho amino acid analysis demonstrated that the population of Raf-1 molecules recognized by the anti-Tyr(P) antiserum was phosphorylated on both tyrosine and serine residues (Fig. 4D) . The amount of 32P-labeled Raf-1 protein in the anti-Tyr(P) immunoprecipitates represented only a fraction of the total 32P-labeled cellular Raf-1 molecules observed in the anti-Raf-1 immunoprecipitates. In anti-Raf-1 immunoprecipitates from the PDGF-stimulated cells, we detected threonine phosphorylation and large increases in serine phosphorylation as compared to the quiescent 3T3 cells (Fig. 4D) . Similar increases in serine and threonine phosphorylation were also observed in anti-Raf-1 immunoprecipitates from v-src cells (data not shown). We were unable to detect Tyr(P) residues on the Raf-1 protein precipitated with the anti-Raf-1 antiserum from PDGF-treated BALB/3T3 cells; however, when cells overproducing the Raf-1 protein (c-raf*) were stimulated with PDGF, Tyr(P) residues were readily apparent in anti-Raf-1 immunoprecipitates (Fig. 4D ). We were unable to detect a band comigrating with Raf-1 in anti-Tyr(P) immunoprecipitates from PMA-, FGF-, or EGF-treated 3T3 cells or in activated c-H-rastransformed 3T3 cells (data not shown). Fig. 5 , the 32p labeling of histone type V-S increased in the anti-Raf-1 immunoprecipitates from v-src-transformed cells and from cells treated with PMA and PDGF when compared to immunoprecipitates from quiescent control cells. Cerenkov counting to measure the 32P radioactivity in the histone bands revealed that PMA and PDGP treatment of cells resulted in a 3-fold increase in histone phosphorylation above basal levels, while v-src transformation resulted in a 5-fold increase (as averaged from four experiments). Phospho amino acid ahalysis of the histone molecules phosphorylated in vitro revealed that serine was the predominant phosphorylated residue. A slight amount of threonine phosphorylation was detected; however, no Tyr(P) residues were observed (data not shown).
DISCUSSION
Cytoplasmic serine/threonine kinases have been postulated to function downstream from membrane events in the mitogenic pathway (24) . We have tested this hypothesis by examining the phosphorylation and protein kinase activity of Raf-1 protein isolated from growth-factor-stimulated and oncogene-transformed cells. Membrane-bound oncogene product expression and growth-factor addition increased the phosphate content and apparent molecular weight of Raf-1 protein whereas nuclear oncogene product expression did not. In addition, Raf-1-associated serine/threonine kinase activity was enhanced by growth-factor treatment and membrane-bound oncogene product expression. These results suggest that Raf-1 molecules receive signals from membranebound receptors and oncogene products and transmit them to as yet unidentified cellular targets. PDGF-treated cells (10 units/ml for 5 min) were assayed for the ability to phosphorylate histone type V-S in vitro as described (8 (6) . Within the amino-terminal domain there is a region rich in serine/threonine residues (9) . The experiments presented here suggest that phosphorylation of these residues may activate Raf-1 protein kinase activity thereby propagating proliferative signals to cellular targets mediating mitogenesis. The importance of the serine/threonine kinase activity to Raf-1 function and the nature of the targets of this activity are presently unknown. The precise role of tyrosine, threonine, and serine phosphorylation in modulating Raf-1 activity will be determined by mutational analysis of the Raf-1 protein.
The Role of Raf-i as a Signal Transducer. Our results indicate that there is a correlation between proliferative events generated at the membrane and alterations in the Raf-1 protein, including activation of the Raf-1 associated serine/ threonine kinase activity. Since the expression of nuclear oncogene products did alter Raf-1 protein phosphorylation, we hypothesize that the Raf-1 protein is involved in the mediation of proliferative signals generated at the membrane but not in the mediation of proliferative signals originating in the nucleus. Other experiments suggest that the raf gene product functions downstream of membrane-associated oncogene products in the signal-transduction pathway (6, 24) . In studies by Smith et al. (24) , microinjected antibodies directed against Raf-1 were able to inhibit the growth of cells transformed by v-ras and v-src but not those transformed by v-raf.
The investigators concluded that the v-raf protein either acts independently of p21c-1s or that it functions downstream of p21C1-s. The experiments presented here, showing Raf-1 protein phosphorylation in response to activated c-Ha-ras protein expression, suggest the latter possibility. We propose that the activation of Raf-1 by mitogenic stimuli at the membrane provides another route of signal transduction to the nucleus. This route would function in addition to the well established pathways mediated by protein kinases C and A and the calcium-regulated kinases.
